Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Novartis Shells Out $210M for Two of Incyte’s Hematology-Oncology Candidates

Deal covers non-U.S. development of Phase III-stage JAK1/JAK2 inhibitor, and global rights to cMET antagonist.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll